Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Earlier, Paratek Pharmaceuticals To Acquire Optinose In Deal Worth Up To $330M, Including $9 Cash And Potential $5/Share In Future Milestones

Author: Benzinga Newsdesk | March 20, 2025 01:19am

Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10‑million‑patient market
Acquisition advances Paratek's vision to become a multi-product company focused on innovative specialty therapies
Total transaction value of up to ~$330 million
Potential consideration of up to $14 per share, including upfront consideration of $9 per share, representing a 50% premium to Optinose's closing trading price on March 19, 2025

Posted In: OPTN